Use of serum markers in prediction of survival in the trapeze factorial trial evaluating docetaxel with zoledronic acid, strontium-89, or both in castrate-refractory prostate cancer (CRPC) metastatic to bone.
Vivek K Wadhwa
No relevant relationships to disclose
Sarah Pirrie
No relevant relationships to disclose
Kai Sheng Wen
No relevant relationships to disclose
Darren Barton
No relevant relationships to disclose
Nicholas David James
No relevant relationships to disclose